[Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
Wide inter-individual difference has been documented for various drug metabolizing enzymes(DMEs) and drug transporters. Some of the single nucleotide polymorphisms(SNPs) existing in the genes encoding DMEs and drug transporters have been associated with the deficiency of DMEs and the transporters. In the case of therapeutic drugs that undergo metabolism by a single DME, serious adverse effect might occur for patients who are devoid of the DME. Function of a number of DMEs and transporters are likely to affect drug effectiveness of three anti-cancer agents, irinotecan, taxol and 5-fluorouracil. Genetic polymorphisms of the genes related to the effectiveness of these drugs are discussed from the aspect of effects of the genetic polymorphisms on their metabolism and disposition.
Ozawa
Shogo
S
Division of Pharmacology, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501.
D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D002352:Carrier Proteins / Q000235:genetics*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D013810:Therapeutic Equivalency
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D003577:Cytochrome P-450 Enzyme System